Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Biomaterials ; 304: 122408, 2024 01.
Artigo em Inglês | MEDLINE | ID: mdl-38041911

RESUMO

The limitations of traditional two-dimensional (2D) cultures and animal testing, when it comes to precisely foreseeing the toxicity and clinical effectiveness of potential drug candidates, have resulted in a notable increase in the rate of failure during the process of drug discovery and development. Three-dimensional (3D) in-vitro models have arisen as substitute platforms with the capacity to accurately depict in-vivo conditions and increasing the predictivity of clinical effects and toxicity of drug candidates. It has been found that 3D models can accurately represent complex tissue structure of human body and can be used for a wide range of disease modeling purposes. Recently, substantial progress in biomedicine, materials and engineering have been made to fabricate various 3D in-vitro models, which have been exhibited better disease progression predictivity and drug effects than convention models, suggesting a promising direction in pharmaceutics. This comprehensive review highlights the recent developments in 3D in-vitro tissue models for preclinical applications including drug screening and disease modeling targeting multiple organs and tissues, like liver, bone, gastrointestinal tract, kidney, heart, brain, and cartilage. We discuss current strategies for fabricating 3D models for specific organs with their strengths and pitfalls. We expand future considerations for establishing a physiologically-relevant microenvironment for growing 3D models and also provide readers with a perspective on intellectual property, industry, and regulatory landscape.


Assuntos
Bioimpressão , Engenharia Tecidual , Animais , Humanos , Engenharia Tecidual/métodos , Bioimpressão/métodos , Descoberta de Drogas , Avaliação Pré-Clínica de Medicamentos , Impressão Tridimensional
2.
Eur J Pharmacol ; 853: 84-92, 2019 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-30880182

RESUMO

Overexpression of connexin 43 (Cx43) was related to dysfunction of vascular smooth muscle cells (VSMCs). Our previous study reported that rutaecarpine, an active ingredient of herbal medicine Evodia, modulated connexins expression in human umbilical vein endothelial cells. This study aims to explore the effects of rutaecarpine on Cx43 expression and VSMCs dysfunction induced by oxidized low-density lipoprotein (ox-LDL). In cultured rat thoracic aortic VSMCs, ox-LDL upregulated the level of Cx43 in a time- and dose-dependent manner, which were abolished by the NF-κB inhibitor BAY11-7082 and PDTC. Furthermore, exposure to ox-LDL for 4 h induced the nuclear translocation of the NF-κB p65 in VMSCs. Ox-LDL (50 mg/l,48 h) induced dysfunction of VSMCs, demonstrated as excessive proliferation, migration, and phenotype switch of cells, which were attenuated by treatment with Cx43 gap junction blocker Gap26(100 µM)) or rutaecarpine (1, 3, and 10 µM). Rutaecarpine inhibited ox-LDL-induced upregulation of Cx43, prevented nuclear translocation of the NF-κB p65, and increased intracellular calcium level in VSMCs. These effects were abolished by pretreatment with transient receptor potential vanilloid subtype 1 (TRPV1) antagonist capsazepine, intracellular calcium chelator BAPTA-AM or CaM antagonist W-7. In conclusion, this study demonstrated that rutaecarpine inhibited Cx43 overexpression through TRPV1/[Ca2+]i/CaM/NF-κB signal pathway, thereby preventing VSMCs dysfunction induced by ox-LDL. Our study provides a novel mechanism by which rutaecarpine modulate Cx43 expression and VSMC function.


Assuntos
Conexina 43/metabolismo , Regulação da Expressão Gênica/efeitos dos fármacos , Alcaloides Indólicos/farmacologia , Lipoproteínas LDL/efeitos adversos , Músculo Liso Vascular/citologia , Quinazolinas/farmacologia , Animais , Movimento Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Relação Dose-Resposta a Droga , Masculino , NF-kappa B/metabolismo , Fenótipo , Ratos , Ratos Sprague-Dawley , Canais de Cátion TRPV/metabolismo , Regulação para Cima/efeitos dos fármacos
3.
Nanomedicine ; 14(5): 1679-1693, 2018 07.
Artigo em Inglês | MEDLINE | ID: mdl-29684526

RESUMO

Melanoma is significantly associated with mutant BRAF gene, a suitable target for siRNA-based anti-melanoma therapy. However, a tumor-specific delivery system is a major hurdle for clinical applications. Here, we developed a novel nano-carrier, FA-GNR-siBRAF for safe topical application, which consists of folic acid (FA) as the tumor-targeting moiety, golden nanorods (GNR) providing photothermal capability to kill tumor cells under laser irradiation, and siRNA specifically silencing BRAF (siBRAF). The in vitro and in vivo results revealed that FA-GNR-siBRAF displayed high transfection rates, and subsequently induced remarkable gene knockdown of BRAF, resulting in suppression of melanoma growth due to the interruption of the MEK/ERK pathway. Combinatorial photothermal effects and BRAF knockdown by FA-GNR-siBRAF effectively killed tumor cells through apoptosis, with enhanced efficiency than individual treatments. Therefore, the FA-GNR-siBRAF simultaneously induced BRAF gene silencing and photothermal effects which achieved synergistic efficacy in the treatment of melanoma, paving a new path for developing clinical treatment methods for melanoma.


Assuntos
Ácido Fólico/química , Inativação Gênica , Hipertermia Induzida , Melanoma Experimental/terapia , Nanotubos/química , Proteínas Proto-Oncogênicas B-raf/antagonistas & inibidores , RNA Interferente Pequeno/genética , Animais , Apoptose , Terapia Combinada , MAP Quinases Reguladas por Sinal Extracelular/antagonistas & inibidores , MAP Quinases Reguladas por Sinal Extracelular/genética , Feminino , Ouro/química , MAP Quinase Quinase 1/antagonistas & inibidores , MAP Quinase Quinase 1/genética , Camundongos , Camundongos Endogâmicos C57BL , Fototerapia , Proteínas Proto-Oncogênicas B-raf/genética , Células Tumorais Cultivadas
4.
Int J Parasitol Drugs Drug Resist ; 6(1): 35-43, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-27054062

RESUMO

In schistosomiasis, egg-induced hepatic granuloma formation is a cytokine-mediated, predominantly CD4(+) Th2 immune response that can give rise to hepatic fibrosis. Hepatic fibrosis is the main cause of increased morbidity and mortality in humans with schistosome infection. Taurine has various physiological functions and hepatoprotective properties as well as anti-inflammatory and immunomodulatory activity. However, little is known about the role of taurine in schistosome egg-induced granuloma formation and fibrosis. We aimed to evaluate the therapeutic potential of taurine as preventative treatment for Schistosoma japonicum infection. Mice infected with S. japonicum cercariae were supplied with taurine drinking water (1% w/v) for 4 weeks starting at 4 weeks post-infection. Taurine supplementation significantly improved the liver pathologic findings, reduced the serum levels of aminotransferases and area of hepatic granuloma, and prevented fibrosis progression. In addition, taurine decreased the expression of the granulomatous and fibrogenic mediators transforming growth factor ß1, tumor necrosis factor α, monocyte chemotactic protein 1α and macrophage inflammatory protein 1α as well as the endoplasmic reticulum stress marker glucose-regulated protein 78. Thus, taurine can significantly attenuate S. japonicum egg-induced hepatic granuloma and fibrosis, which may depend in part on the downregulation of some relevant cytokine/chemokines and reducing the endoplasmic reticulum stress response.


Assuntos
Água Potável , Granuloma/tratamento farmacológico , Esquistossomose Japônica/tratamento farmacológico , Taurina/administração & dosagem , Taurina/uso terapêutico , Administração Oral , Animais , Cercárias , Quimiocinas/genética , Citocinas/genética , Granuloma/parasitologia , Humanos , Cirrose Hepática/tratamento farmacológico , Cirrose Hepática/parasitologia , Camundongos , Contagem de Ovos de Parasitas , Schistosoma japonicum/efeitos dos fármacos , Esquistossomose Japônica/prevenção & controle , Transaminases/sangue , Fator de Crescimento Transformador beta1/genética , Fator de Necrose Tumoral alfa/genética
5.
J Cardiovasc Pharmacol ; 67(6): 519-25, 2016 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26859198

RESUMO

Adhesion of monocytes to the vascular endothelium is crucial in atherosclerosis development. Connexins (Cxs) which form hemichannels or gap junctions, modulate monocyte-endothelium interaction. We previously found that rutaecarpine, an active ingredient of the Chinese herbal medicine Evodia, reversed the altered Cx expression induced by oxidized low-density lipoprotein (ox-LDL) in human umbilical vein endothelial cells, and consequently decreases the adhesive properties of endothelial cells to monocytes. This study further investigated the effect of rutaecarpine on Cx expression in monocytes exposed to ox-LDL. In cultured human monocytic cell line THP-1, ox-LDL rapidly reduced the level of atheroprotective Cx37 but enhanced that of atherogenic Cx43, thereby inhibiting adenosine triphosphate release through hemichannels. Pretreatment with rutaecarpine recovered the expression of Cx37 but inhibited the upregulation of Cx43 induced by ox-LDL, thereby improving adenosine triphosphate-dependent hemichannel activity and preventing monocyte adhesion. These effects of rutaecarpine were attenuated by capsazepine, an antagonist of transient receptor potential vanilloid subtype 1. The antiadhesive effects of rutaecarpine were also attenuated by hemichannel blocker 18α-GA. This study provides additional evidence that rutaecarpine can modulate Cx expression through transient receptor potential vanilloid subtype 1 activation in monocytes, which contributes to the antiadhesive properties of rutaecarpine.


Assuntos
Conexinas/efeitos dos fármacos , Endotélio Vascular/metabolismo , Alcaloides Indólicos/farmacologia , Lipoproteínas LDL/metabolismo , Monócitos/metabolismo , Quinazolinas/farmacologia , Trifosfato de Adenosina/metabolismo , Aterosclerose/fisiopatologia , Células Cultivadas , Relação Dose-Resposta a Droga , Humanos , Fatores de Tempo
6.
Technol Health Care ; 24 Suppl 1: S415-20, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26578278

RESUMO

RNA interference (RNAi) employs double-stranded RNA or siRNA (small interfering RNA) to silence gene expression in cells. The widespread use of RNAi therapeutics requires the development of clinically suitable, safe and effective delivery vehicles. PEI (Poly(ethylene imine)) carrying the positive charges has attracted considerable attention for siRNA delivery. Gold nanorods (GNRs) exhibit specially localized surface plasmon resonance when excited by the visible and near-infrared laser, which is useful for photothermal therapy. However, the toxicity derived from a large amount of the surfactant cetyltrimethylammonium bromide (CTAB) during GNR synthesis severely limits their medical applications. Here, we report the synthesis of GNRs-PEI/GNRs-PEI-folate to improve biocompatibility, siRNA delivery and photothermal therapy of GNRs. Firstly, GNRs were synthesized according to the seed-mediated template-assisted protocol. The characterization results of GNRs showed: the size was length about 218 nm and width about 26.8 nm; the Zeta potential was +38.1 mV derived from CTAB on their surface; the dipole resonance extinction spectrum peak was 752 nm which is effective for photothermal therapy in vivo. Secondly, we synthesized PEI-MUA (Mercaptoundecanoic acid) and PEI-MUA-folate based on the chemical reaction between amino group of PEI and carboxyl group of MUA or Folate. PEI-MUA or PEI-MUA-folate to replace CTAB on GNRs obtained the GNRs-MUA-PEI system or the GNRs-MUA-PEI-folate system due to the solid conjugation between the thiol group of MUA and GNRs. The products were measured using the FTIR Spectrometer, and the spectra suggest MUA-PEI or PEI-MUA-folate has successfully replaced CTAB on the surface of GNRs. Finally, GNRs-MUA-PEI was incubated with siRNA-Cy3. The unbound siRNA-Cy3 was measured the intensity of fluorescence for calculating the uploaded amount of siRNA by GNRs-MUA-PEI, and the results indicate that the uploaded percentage of siRNA is about 70%. We conclude that the GNRs-MUA-PEI system is an effective siRNA loading vehicle.


Assuntos
Ouro/química , Nanotubos/química , Fototerapia/métodos , Polietilenos/química , RNA Interferente Pequeno/administração & dosagem , Sobrevivência Celular , Cetrimônio , Compostos de Cetrimônio/química , Ácido Fólico/química , Humanos , Tamanho da Partícula , Propriedades de Superfície
7.
Parasitol Res ; 112(10): 3457-63, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23832642

RESUMO

The parasitic nematode Trichinella spiralis can cause trichinellosis, which leads to pathological processes in the intestine and muscle. The intestinal invasion determines the development, subsequent course, and consequences of the disease. Gastrointestinal nematode infection, including with T. spiralis, is accompanied by a rapid and reversible expansion of mucosal mast cell and goblet cell in the intestinal epithelium, which play important roles in the host immune response to parasite and worm expulsion from the intestine. Taurine and its derivatives have anti-infection and anti-inflammatory properties. We investigated whether taurine supplementation in mice could influence the development and pathological processes of infection with T. spiralis. Supplementing 1% taurine in drinking water in mice infected with T. spiralis could alleviate the burden of intestinal adult worms on days 7 and 10 postinfection (all p < 0.01) and the formation of infective muscle larvae in striated muscle during T. spiralis infection (p < 0.01). As compared with T. spiralis infection alone, taurine treatment increased the number of goblet cells on days 7, 10, and 15 (p < 0.01 and p < 0.05) and alleviated intestinal mucosal mast cell hyperplasia on days 10 and 15 (all p < 0.01). So taurine supplementation in drinking water increased infection-induced intestinal goblet cell hyperplasia and ameliorated mucosal mastocytosis. Thus, taurine can ameliorate the pathological processes of trichinellosis and may be of great value for the treatment and prevention of infection with T. spiralis and other gastrointestinal nematodes.


Assuntos
Água Potável/química , Enteropatias Parasitárias/tratamento farmacológico , Taurina/farmacologia , Triquinelose/tratamento farmacológico , Animais , Feminino , Enteropatias Parasitárias/parasitologia , Intestinos/citologia , Intestinos/patologia , Mastócitos/citologia , Mastócitos/patologia , Mastocitose/tratamento farmacológico , Camundongos , Camundongos Endogâmicos ICR , Músculo Esquelético/parasitologia , Taurina/administração & dosagem , Taurina/química , Trichinella spiralis , Triquinelose/parasitologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA